drugset
drugset / Trial / NCT00210392

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

NCT00210392 ↗

Phase 2 Terminated 12 enrolled International Extranodal Lymphoma Study Group (IELSG)
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to assess the antitumor activity (in terms of overall response rate - ORR - i.e. sum of complete and partial responses) of bortezomib in pretreated MALT lymphomas with more than one prior systemic therapy regimen

Timeline

Start
2005-07
Primary completion
2007-11
Completion
2007-11

Outcome

Outcome not reported

Stopped: “After IELSG25A study amendment, patients subject of the present study were eligible for inclusion in the IELSG25A study”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 1.3 mg/m2 Intravenous

Indications

MALT lymphoma